Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation

Journal of Genetic Counseling

Volumn 26, Issue 1, 2017, Pages 79-92

  Buchanan, Adam H ^a   Voils, Corrine I ^b,c   Schildkraut, Joellen M ^c   Fine, Catherine ^d   Horick, Nora K ^e   Marcom, P Kelly ^c   Wiggins, Kristi ^c   Skinner, Celette Sugg ^f  

^a GEISINGER HEALTH SYSTEM   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

BRCA1 gene; BRCA2 gene; Breast cancer; Genetic counseling; Ovarian cancer

Indexed keywords

ADULT; BREAST TUMOR; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; MUTATION; OVARY TUMOR; RISK REDUCTION; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MUTATION; OVARIAN NEOPLASMS; RISK REDUCTION BEHAVIOR;

EID: 85010700002     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-016-9981-6     Document Type: Article

References (76)

1. American Society of Clinical Oncology (2003). American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21(12), 2397–2406. doi:10.1200/jco.2003.03.189.
2. Berliner, J. L., Fay, A. M., & Practice Issues Subcommittee of the National Society of Genetic Counselors’ Familial Cancer Risk Counseling Special Interest, G (2007). Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 16(3), 241–260.
3. Berliner, J. L., Fay, A. M., Cummings, S. A., Burnett, B., & Tillmanns, T. (2013). NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. Journal of Genetic Counseling, 22(2), 155–163.
4. Botkin, J. R., Smith, K. R., Croyle, R. T., Baty, B. J., Wylie, J. E., Dutson, D., et al. (2003). Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet Part A, 118(3), 201–209.
5. Bradbury, A. R., Ibe, C. N., Dignam, J. J., Cummings, S. A., Verp, M., White, M. A., et al. (2008). Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine, 10(3), 161–166.
6. Buchanan, A. H., Skinner, C. E., Calingaert, B., Schildkraut, J. M., King, R. H., & Marcom, P. K. (2009). Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Commun Oncol(6), 70–77.
7. Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J., Lynch, P., et al. (1997). Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer genetics studies consortium. JAMA, 277(12), 997–1003.
8. Caiata-Zufferey, M., & Pagani, O. (2015). Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. Genetics in Medicine, 17(9), 726–732. doi:10.1038/gim.2014.183.
9. Calzone, K. A., Prindiville, S. A., Jourkiv, O., Jenkins, J., DeCarvalho, M., Wallerstedt, D. B., et al. (2005). Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer. Journal of Clinical Oncology, 23(15), 3455–3464.
10. Caplan, L. S., McQueen, D. V., Qualters, J. R., Leff, M., Garrett, C., & Calonge, N. (2003). Validity of women’s self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiology, Biomarkers & Prevention, 12(11 Pt 1), 1182–1187.
11. CDC. (2014, September 8, 2014). Office of Public Health Genomics - Genomic Tests and Family History by Levels of Evidence. Retrieved April 28, 2015, from http://www.cdc.gov/genomics/gtesting/tier.htm
12. Chagpar, A. B., Polk Jr., H. C., & McMasters, K. M. (2008). Racial trends in mammography rates: a population-based study. Surgery, 144(3), 467–472.
13. Chen, S., & Parmigiani, G. (2007). Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology, 25(11), 1329–1333.
14. Claes, E., Evers-Kiebooms, G., Decruyenaere, M., Denayer, L., Boogaerts, A., Philippe, K., et al. (2005). Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behavioral Medicine, 31(3), 93–105.
15. Finch, A., Beiner, M., Lubinski, J., Lynch, H. T., Moller, P., Rosen, B., et al. (2006). Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA, 296(2), 185–192.
16. Finch, A. P., Lubinski, J., Moller, P., Singer, C. F., Karlan, B., Senter, L., et al. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 32(15), 1547–1553.
17. Friebel, T. M., Domchek, S. M., Neuhausen, S. L., Wagner, T., Evans, D. G., Isaacs, C., et al. (2007). Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clinical Breast Cancer, 7(11), 875–882.
18. Garcia, C., Wendt, J., Lyon, L., Jones, J., Littell, R. D., Armstrong, M. A., et al. (2014). Risk management options elected by women after testing positive for a BRCA mutation. Gynecologic Oncology, 132(2), 428–433.
19. Hadley, D. W., Jenkins, J. F., Dimond, E., de Carvalho, M., Kirsch, I., & Palmer, C. G. (2004). Colon Cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology, 22(1), 39–44.
20. Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics, 42(2), 377–381.
21. Horowitz, M. J., Wilner, N., & Alvarez, W. (1979). Impact of event scale: a measure of subjective stress. Psychosomatic Medicine, 41(3), 209–218.
22. Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277–1288.
23. Hughes, C., Lerman, C., Schwartz, M., Peshkin, B., Wenzel, L., Narod, S., et al. (2002). All in the family: evaluation of the processand content of sisters’ communication about BRCA1 and BRCA2 genetic test results. American Journal of Medical Genetics, 107, 143–150.
24. Julian-Reynier, C., Bouhnik, A. D., Mouret-Fourme, E., Gauthier-Villars, M., Berthet, P., Lasset, C., et al. (2010). Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genetics in Medicine, 12(12), 801–807.
25. Khoury, M. J., Coates, R. J., & Evans, J. P. (2010). Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genetics in Medicine, 12(11), 680–683.
26. King, E. S., Rimer, B. K., Trock, B., Balshem, A., & Engstrom, P. (1990). How valid are mammography self-reports? American Journal of Public Health, 80(11), 1386–1388.
27. Kinney, A. Y., Simonsen, S. E., Baty, B. J., Mandal, D., Neuhausen, S. L., Seggar, K., et al. (2006). Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred. Journal of Genetic Counseling, 15(4), 293–305.
28. Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. Journal of Clinical Oncology, 28(2), 222–231.
29. Leonarczyk, T. J., & Mawn, B. E. (2015). Cancer risk management decision making for BRCA+ women. Western Journal of Nursing Research, 37(1), 66–84.
30. Lerman, C., Hughes, C., Croyle, R. T., Main, D., Durham, C., Snyder, C., et al. (2000). Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Preventive Medicine, 31(1), 75–80.
31. Lodder, L. N., Frets, P. G., Trijsburg, R. W., Meijers-Heijboer, E. J., Klijn, J. G., Seynaeve, C., et al. (2002). One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Research and Treatment, 73(2), 97–112.
32. Meijers-Heijboer, E. J., Verhoog, L. C., Brekelmans, C. T., Seynaeve, C., Tilanus-Linthorst, M. M., Wagner, A., et al. (2000). Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet, 355(9220), 2015–2020.
33. Meijers-Heijboer, H., Brekelmans, C. T., Menke-Pluymers, M., Seynaeve, C., Baalbergen, A., Burger, C., et al. (2003). Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 21(9), 1675–1681.
34. Metcalfe, K. A., Birenbaum-Carmeli, D., Lubinski, J., Gronwald, J., Lynch, H., Moller, P., et al. (2008). International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 122(9), 2017–2022.
35. Miranda, P. Y., Tarraf, W., & Gonzalez, H. M. (2011). Breast cancer screening and ethnicity in the United States: implications for health disparities research. Breast Cancer Research and Treatment, 128(2), 535–542.
36. Montano, D. E., & Phillips, W. R. (1995). Cancer screening by primary care physicians: a comparison of rates obtained from physician self-report, patient survey, and chart audit. American Journal of Public Health, 85(6), 795–800.
37. NCCN. (2000, 06/01/00). NCCN Practice Guidelines: Genetics/Familial High-Risk Cancer Screening. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
38. NCCN. (2001, 04/19/01). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Screening: Breast Version 1.2001. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
39. NCCN. (2002, 04/22/02). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast Version 1.2002. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
40. NCCN. (2005, 09/09/05). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2005. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
41. NCCN. (2006, 12/14/05). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2006. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
42. NCCN. (2010, 03/08/10). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2010. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
43. NCCN. (2012, 05/02/12). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2012. RetrievedNCCN August 16, 2012, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
44. NCCN. (2003, 07/28/03). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2003. Retrieved February, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
45. NCCN. (2015, 3/30/15). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2015. Retrieved April 30, 2015, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
46. O’Neill, S. C., Valdimarsdottir, H. B., Demarco, T. A., Peshkin, B. N., Graves, K. D., Brown, K., et al. (2010). BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Research and Treatment, 124(3), 755–764.
47. Onwuegbuzie, A. (2003). Effect sizes in qualitative research: a prolegomenon. Quality & Quantity, 37(4), 393–409.
48. Pal, T., Lee, J. H., Besharat, A., Thompson, Z., Monteiro, A. N., Phelan, C., et al. (2014). Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clinical Genetics, 85(1), 49–53.
49. Patenaude, A. F., Dorval, M., DiGianni, L. S., Schneider, K. A., Chittenden, A., & Garber, J. E. (2006). Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. Journal of Clinical Oncology, 24(4), 700–706.
50. Peshkin, B. N., Schwartz, M. D., Isaacs, C., Hughes, C., Main, D., & Lerman, C. (2002). Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiology, Biomarkers & Prevention, 11(10 Pt 1), 1115–1118.
51. Petrucelli, N., Daly, M. B., & Feldman, G. L. (2013). BRCA1 and BRCA2 hereditary breast and ovarian cancer. In R. A. Pagon, M. P. Adam, H. H. Ardinger, S. E. Wallace, A. Amemiya, L. J. H. Bean, T. D. Bird, C. T. Fong, R. J. H. Smith & K. Stephens (Eds.), GeneReviews(R). Seattle (WA): University of Washington, Seattle University of Washington, Seattle. All rights reserved.
52. Phillips, K. A., Jenkins, M. A., Lindeman, G. J., McLachlan, S. A., McKinley, J. M., Weideman, P. C., kConFab, I. (2006). Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clinical Genetics, 70(3), 198–206.
53. Rauscher, G. H., Johnson, T. P., Cho, Y. I., & Walk, J. A. (2008). Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiology, Biomarkers & Prevention, 17(4), 748–757.
54. Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ‘t Veer, L., Garber, J. E., Weber, B. L. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. Journal of Clinical Oncology, 22(6), 1055–1062.
55. Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80–87.
56. Riley, B. D., Culver, J. O., Skrzynia, C., Senter, L. A., Peters, J. A., Costalas, J. W., et al. (2012). Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 21(2), 151–161.
57. Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., Offit, K., & American Society of Clinical Oncology (2009). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901.
58. Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., et al. (2002). Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of Clinical Oncology, 20(5), 1260–1268.
59. Schmeler, K. M., Sun, C. C., Bodurka, D. C., White, K. G., Soliman, P. T., Uyei, A. R.,. Lu, K. H. (2006). Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstetrics and Gynecology, 108(3 Pt 1), 515–520.
60. Schwartz, M. D., Isaacs, C., Graves, K. D., Poggi, E., Peshkin, B. N., Gell, C., et al. (2012). Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer, 118(2), 510–517.
61. Schwartz, M. D., Kaufman, E., Peshkin, B. N., Isaacs, C., Hughes, C., DeMarco, T., et al. (2003). Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. Journal of Clinical Oncology, 21(21), 4034–4041.
62. Schwartz, M. D., Lerman, C., Brogan, B., Peshkin, B. N., Halbert, C. H., DeMarco, T., et al. (2004). Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. Journal of Clinical Oncology, 22(10), 1823–1829.
63. Sidon, L., Ingham, S., Clancy, T., Clayton, R., Clarke, A., Jones, E. A., et al. (2012). Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. British Journal of Cancer, 106(4), 775–779.
64. Skinner, C., Rawl, S., Moser, B., Buchanan, A., Scott, L., Champion, V., et al. (2005). Impact of the cancer risk intake system on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. Journal of General Internal Medicine, 20(4), 360–365.
65. Skinner, C. S., Buchanan, A., Champion, V., Monahan, P., Rawl, S., Springston, J., et al. (2011). Process outcomes from a randomized controlled trial comparing tailored mammography interventions delivered via telephone vs. DVD. Patient Educ Couns, 85(2), 308–312.
66. Skinner, C. S., Tiro, J., & Champion, V. L. (2015). The health belief model. In K. Glanz, B. K. Rimer, & K. Viswanath (Eds.), Health Behavior Theory, Research, and Practice (5th ed., pp. 75–94). San Francisco, CA: Jossey-Bass.
67. Spielberger, C. D., Gorsuch, R., Lushene, R., & al., e. (1983). State-Trait Anxiety Inventory for Adults: Sampler Set - Manual, Test, Scoring Key. Palo Alto, CA: Mind Garden.
68. Tinley, S. T., Houfek, J., Watson, P., Wenzel, L., Clark, M. B., Coughlin, S., et al. (2004). Screening adherence in BRCA1/2 families is associated with primary physicians’ behavior. American Journal of Medical Genetics. Part A, 125A(1), 5–11.
69. Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S. C., et al. (2004). Genetic cancer risk assessment and counseling: recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 13(2), 83–114.
70. Uyei, A., Peterson, S. K., Erlichman, J., Broglio, K., Yekell, S., Schmeler, K.,. Arun, B. (2006). Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer, 107(12), 2745–2751.
71. Ware Jr., J., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.
72. Warner, E., Hill, K., Causer, P., Plewes, D., Jong, R., Yaffe, M., et al. (2011). Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. Journal of Clinical Oncology, 29(13), 1664–1669.
73. Watson, M., Kash, K. M., Homewood, J., Ebbs, S., Murday, V., & Eeles, R. (2005). Does genetic counseling have any impact on management of breast cancer risk? Genetic Testing, 9(2), 167–174.
74. Willis, G. B. (2005). Cognitive interviewing. Thousand Oaks, CA: SAGE Publications.
75. Yerkes, R. M., & Dodson, J. D. (1908). The relation of strength of stimulus to rapidity of habit-formation. Journal of Comparative Neurology and Psychology, 18, 459–482.
76. Zapka, J. G., Bigelow, C., Hurley, T., Ford, L. D., Egelhofer, J., Cloud, W. M., et al. (1996). Mammography use among sociodemographically diverse women: the accuracy of self-report. American Journal of Public Health, 86(7), 1016–1021.